Innate Pharma SA, a biotechnology company, discovers, develops and markets therapeutic antibodies for the treatment of oncological indications in France and internationally. The company is headquartered in Marseille, France.
| Revenue (TTM) | $9.01M |
| Gross Profit (TTM) | $-34.62M |
| EBITDA | $-53.31M |
| Operating Margin | -690.00% |
| Return on Equity | -271.40% |
| Return on Assets | -38.90% |
| Revenue/Share (TTM) | $0.10 |
| Book Value | $-0.27 |
| Price-to-Book | 20.10 |
| Price-to-Sales (TTM) | 23.57 |
| EV/Revenue | 58.39 |
| EV/EBITDA | -6.94 |
| Quarterly Earnings Growth (YoY) | -74.70% |
| Quarterly Revenue Growth (YoY) | -46.70% |
| Shares Outstanding | $93.90M |
| Float | $70.57M |
| % Insiders | 1.67% |
| % Institutions | 0.46% |
Volatility is currently expanding
Innate Pharma NASDAQ: IPHA said it has raised €30 million in equity financing, providing funding to advance its strategic priorities, including the development of its lacutamab and IPH4502 programs and its preclinical antibody-drug conjugate, or ADC, portfolio.
Innate Pharma S.A. (IPHA) Discusses EUR 30 Million Equity Raise, Strategic Partnership and Pipeline Advancement Transcript
MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma announces conference call and webcast.
STOCKHOLM, Aug. 10, 2026 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) and Innate Pharma SA (Euronext Paris: IPH) (NASDAQ: IPHA) ("Innate" or the "Company") today announced that they have entered a strategic partnership to enable initiation of the TELLOMAK-3 confirmatory Phase 3 study in cutaneous T cell lymphoma (CTCL), a key step toward filing for accelerated approval of lacutamab in Sézary syndrome, a subtype of CTCL. Under the agreement, Innate will conduct the TELLOMAK-3 Phase 3 confirmatory trial in cutaneous T-cell lymphoma, supporting a planned accelerated approval filing in Sézary syndrome.
Innate Pharma has an interesting lineup of catalysts with the upcoming IPH4502 data, PACIFIC-9 results, and a potential financing solution for TELLOMAK-3. IPH4502's early responses across several solid tumors also give it some diversification beyond Monalizumab. PACIFIC-9 is IPHA's largest near-term catalyst, but AstraZeneca controls it, and IPHA is only eligible for milestone payments and royalties if it succeeds.
MARSEILLE, France--(BUSINESS WIRE)-- #Cancer--Innate Pharma to participate in a bladder cancer panel at the BTIG Virtual Biotechnology Conference.
Innate Pharma NASDAQ: IPHA said its first-quarter 2026 business update centered on three priority clinical assets: lacutamab in cutaneous T-cell lymphoma, the Nectin-4 antibody-drug conjugate IPH4502 in advanced solid tumors, and the AstraZeneca-partnered monalizumab program in non-small cell lung cancer.
MARSEILLE, France--(BUSINESS WIRE)---- $IPH #ADC--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today reported its business update and consolidated financial results for the quarter ending March 31, 2026. “We have continued to make solid progress across our priority clinical assets during the first quarter. We are approaching completion of enrollment in the Phase 1 dose escalation and backfill cohorts for IPH4502. In parallel, we have advanced the negotiati.
MARSEILLE, France--(BUSINESS WIRE)--Number of shares and voting rights of Innate Pharma as of April 16, 2026.
MARSEILLE, France--(BUSINESS WIRE)---- $Innate #Biotech--Innate Pharma announces conference call and webcast for Q1 2026 Business Update.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on IPHA and any ticker you trade — then tracks every position and per-strategy win rate.
